Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov |
Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby |
LOBBYING REGISTRATION
Lobbying Disclosure Act of 1995 (Section 4)
1. Effective Date of Registration | 05/19/2008 |
||||
2. House Identification | 34506 |
Senate Identification | 48793 |
REGISTRANT Organization/Lobbying Firm Self Employed Individual
3. Registrant | Organization | ACADEMY OF MANAGED CARE PHARMACY |
Address | 100 NORTH PITT STREET, #400 |
Address2 | |
City | ALEXANDRIA |
State | VA |
Zip | 22314 |
Country | USA |
4. Principal place of business (if different than line 3)
City | |
State | |
Zip | |
Country | |
5. Contact name and telephone number | International Number |
Contact | Mr. William Hermelin |
Telephone | 7036838416 |
bhermelin@amcp.org |
CLIENT A Lobbying Firm is required to file a separate registration for each client. Organizations employing in-house lobbyists should check the box labeled “Self” and proceed to line 10. Self
7. Client name | ACADEMY OF MANAGED CARE PHARMACY |
Address | |
City | |
State | |
Zip | |
Country | USA |
City | |
State | |
Zip | |
Country | |
LOBBYISTS
10. Name of each individual who has acted or is expected to act as a lobbyist for the client identified on line 7. If any person listed in this section has served as a “covered executive branch official” or “covered legislative branch official” within twenty years of first acting as a lobbyist for the client, state the executive and/or legislative position(s) in which the person served.
Name | Covered Official Position (if applicable) | ||
First |
Last |
Suffix |
|
William (Bill) | Hermelin | | |
Melissa | Andel | | |
Ryan | Day | | |
Lauren | Fuller | | Chief Investigative Counsel, U.S. Senate Cmte. on Finance |
| | | |
LOBBYING ISSUES
11. General lobbying issue areas (Select all applicable codes).
HCR |
MMM |
PHA |
|
|
|
|
|
|
12. Specific lobbying issues (current and anticipated)
Proposed changes to the Medicare prescription drug benefit; adjustments to Medicaid prescription drug reimbursement rates; FDA issues, including establishment of a regulatory pathway for approval of "follow-on" biologic drug products, additional monitoring of direct-to-consumer advertisements of prescription drugs and additional agency funding; funding for comparative effectiveness research; health information technology/e-prescribing; importation of prescription drugs/counterfeit drugs
AFFILIATED ORGANIZATIONS
13. Is there an entity other than the client that contributes more than $5,000 to the lobbying activities of the registrant in a quarterly period and either participates in and/or in whole or in major part supervises or controls the registrant’s lobbying activities?
No --> Go to line 14. | Yes --> Complete the rest of this section for each entity matching the criteria above, then proceed to line 14. |
Internet Address: | |
Name | Address | Principal Place of Business | ||||||||
Street | ||||||||||
|
||||||||||
|
|
|
||||||||
|
|
|||||||||
|
|
|
||||||||
|
|
|||||||||
|
|
|
||||||||
|
|
FOREIGN ENTITIES
14. Is there any foreign entity
a) holds at least 20% equitable ownership in the client or any organization identified on line 13; or
b) directly or indirectly, in whole or in major part, plans, supervises, controls, directs, finances or subsidizes activities of the client or any organization identified on line 13; or
c) is an affiliate of the client or any organization identified on line 13 and has a direct interest in the outcome of the lobbying activity?
No --> Sign and date the registration. | Yes --> Complete the rest of this section for each entity matching the criteria above, then sign the registration. |
Address | Ownership | |||||
Name | Street | Principal place of business | Amount of contribution | |||
|
(city and state or country) | for lobbying activities |
|
|
|||||||||||
|
|
|
|
|
% | |||||||
|
|
|||||||||||
|
|
|
|
|
% |
Signature | Digitally Signed By: William Hermelin, Director of Government Relations and General Counsel |
Date | 07/01/2008 |